FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a market perform rating on shares of FibroGen in a research report on Monday, June 3rd.

FibroGen Stock Performance

FibroGen stock opened at $0.40 on Friday. FibroGen has a 52 week low of $0.33 and a 52 week high of $2.93. The stock has a market capitalization of $39.90 million, a P/E ratio of -0.16 and a beta of 0.71. The stock has a fifty day moving average of $0.83 and a 200-day moving average of $1.35.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The business had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same period in the previous year, the firm posted ($0.65) EPS. On average, research analysts forecast that FibroGen will post -1.05 earnings per share for the current year.

Insider Activity

In other FibroGen news, insider Deyaa Adib bought 22,123 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were acquired at an average cost of $1.17 per share, for a total transaction of $25,883.91. Following the transaction, the insider now directly owns 82,123 shares in the company, valued at $96,083.91. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.98% of the stock is currently owned by insiders.

Hedge Funds Weigh In On FibroGen

Hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC increased its position in FibroGen by 23.7% during the 4th quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock valued at $8,654,000 after purchasing an additional 1,872,000 shares during the period. Acadian Asset Management LLC increased its position in shares of FibroGen by 34.4% during the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after buying an additional 860,854 shares during the period. AQR Capital Management LLC raised its stake in FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 769,586 shares during the last quarter. Pennant Investors LP bought a new position in FibroGen during the fourth quarter worth $681,000. Finally, XTX Topco Ltd acquired a new position in FibroGen in the second quarter valued at $424,000. 72.71% of the stock is currently owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.